Taken together, these data indicate that AZD1775 enhances KIL growth control of MOC2 via a tumor cell-dependent mechanism, but is not due to direct MOC2 cytotoxicity or altered expression of MHC class I, PD-L1 or NKG2D ligands. This evidence concerns the gene CD274 and neoplasm.